Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Near Vergence Training for Distance Control in Intermittent Exotropia

23 september 2026 bijgewerkt door: LEUNG Tsz Wing, The Hong Kong Polytechnic University

Evaluating Near Vergence Training for Distance Control in Basic and Divergence Excess Intermittent Exotropia

Intermittent Exotropia (IXT) is a common type of eye misalignment where one eye periodically turns outward, and control is typically much worse when looking at objects far away than close up. However, most currently available training programme are focused on near-viewing tasks. The goal of this clinical trial is to investigate if a new, structured, home-based near eye training program works to improve distance eye alignment control in children and young adults with IXT.

The main questions the study aims to answer are:

  • Does a 12-week near eye training program improve a participant's ability to control their eye alignment when looking at a distance?
  • Does using a special reading glasses during near training help to control distance eye alignment better than doing the training without the reading glasses?
  • Do the benefits of this eye training last after the training has stopped?

This is a two- phase, single- masked (examiner masked), randomized clinical trial with crossover design. The entire study duration is about 24 weeks. A total sample size of 42 participants, aged 6 to 25 years with diagnosed Basic (distance deviation is within 10 prism diopters of the near deviation) or Divergence excess (distance deviation is at least 10 prism diopters greater than the near deviation) IXT, will be recruited.

In Phase I (Weeks 0 to 12), participants will be randomly allocated into one of three groups, with 14 individuals in each group:

  • Group 1 does eye training while wearing special plus-power reading glasses that remove the need to focus up close, mimicking how the eyes look at a distance.
  • Group 2 does the exact same eye training but wears regular distance glasses without the special reading addition.
  • Group 3 serves as a control group that does not do training during the first 12 weeks, but will receive the training in the second phase.

In Phase II (Weeks 13 to 24), which is a crossover phase, groups 1 and 2 will stop training to see if the visual improvements last, while group 3 will be re-randomized into two subgroups (group 3A, with special plus-power reading glasses, and group 3B with regular glasses with distance correction) that will undertake daily eye training for 12 weeks to ensure ethical treatment access. All participants will have a final eye exam at 24 weeks.

During home training, participants will:

  • Wear standard glasses provided by the study.
  • Practice daily, home-based eye exercises for 12 weeks using a standardized software program on a computer or tablet.
  • Complete 3 training sessions every day, lasting 7 minutes per session.
  • Wear red-blue 3D glasses during training and press arrow keys or swipe the screen to play a visual game that dynamically changes in difficulty.

Preliminary test and binocular vision assessment with fixed and uniform sequence will be performed at baseline visit, 6th week interim visit, 12th and 24th week evaluation. All eye examinations will be carried out in The Optometry Centre (A034), the School of Optometry, The Hong Kong Polytechnic University.

The following data will be statistically analyzed. The primary outcome data is distance Office Control Score (OCS) at 12-week visit. Secondary outcomes data include change in deviation angle, near and distance stereopsis and patient- / parent- reported health-related quality-of-life questions at 12-week.

Studie Overzicht

Toestand

Werving

Studietype

Ingrijpend

Inschrijving (Geschat)

42

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Hong Kong, Hongkong
        • Werving
        • The Optometry Clinic, The Hong Kong Polytechnic University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 jaar tot 25 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria

  • Age and Diagnosis: Participants must be aged 6 to ≤ 25 years at the time of screening, with a confirmed clinical diagnosis of either Basic or Divergence Excess (DE) Intermittent Exotropia (IXT).

  • Ocular Alignment Magnitude: Distance exodeviation measuring between 10 and 40 prism diopters (pd) inclusive, determined by the prism and alternate cover test (PACT).

  • Distance-Near Disparity Limits: Near exodeviation must not exceed the distance exodeviation by more than 10 pd (to exclude Convergence Insufficiency type exotropia).

  • Baseline Distance Control: A baseline distance IXT Office Control Score (OCS) between Grade 2 and Grade 4 inclusive, based on the mean of 3 standardized assessments.

  • Baseline Near Control: A baseline near IXT control score less than or equal to the distance IXT control score, based on the mean of 3 standardized assessments.

  • Visual Acuity: Best-corrected visual acuity (BCVA) of Logarithm of the Minimum Angle of Resolution (logMAR) 0.1 or better in each eye at both distance and near fixation.

  • Sensory Status: Measurable near stereoacuity of 400 arc seconds or better on the Preschool Randot stereoacuity test.

  • Refractive Correction Stability: Compliance with wearing a stable, appropriate spectacle correction for ≥ 4 months prior to formal baseline assessment if the participant meets any of the following refractive thresholds:

    • Myopia < -0.50D spherical equivalent (SE) in either eye.
    • Hyperopia > +2.50D SE in either eye.
    • Anisometropia > 1.00 SE.
    • Astigmatism > 1.50D cylinder in either eye.
  • Treatment History: No history of prior non-surgical interventions for IXT, including patching, vision therapy/orthoptics, or overminus lens therapy (≥ 0.50 D).

  • Surgical History: No prior history of strabismus surgery, extraocular muscle botulinum toxin injections, intraocular surgery, or refractive surgery.

  • Trial Commitment: No planned strabismus surgery or conflicting ocular therapies during the 24-week study period.

Exclusion Criteria

  • Amblyopia and Co-morbid Strabismus: Presence of amblyopia, nystagmus, restrictive strabismus, or paretic strabismus.
  • Vertical Misalignment: Presence of an associated vertical ocular deviation > 5 pd.
  • Significant Pathologies: Co-existing significant ocular disease or neurological disorders (e.g., cerebral palsy) that could confound oculomotor or sensory evaluations.
  • Confounding Medications: Regular use of systemic or topical ocular medications known to alter accommodative or vergence function within the 3 months prior to screening (including, but not limited to, atropine, pirenzepine, or systemic anti-epileptic agents).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Active training group with reading glasses

Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence

Standardized home-based near vergence training platform with data visualization tools and communication platforms

Actieve vergelijker: Active training group without reading glasses

Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence

Standardized home-based near vergence training platform with data visualization tools and communication platforms

Geen tussenkomst: Control group

No training will be received in Phase I (Weeks 0 to 12); Will receive training in Phase II of the study (Weeks 13 to 24) to ensure ethical treatment access

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change of Distance Office Control Score
Tijdsspanne: Baseline, 6-week, 12-week and 24-week

Objective and quantitative office control scale, based on the frequency of deviation and the recovery speed followed by occlusion. Ranged from 0 to 5, with score 0 represents the best control (phoria with excellent control), and score 5 represents the worst control (constant exotropia during the 30-second observation)

Baseline, 6-week, 12-week and 24-week

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change of exodeviation magnitude angle
Tijdsspanne: Baseline, 6-week, 12-week and 24-week

measured by Prism and Alternate Cover Test, ranged from 1 to 50 prism diopter. The higher the value, the worse is the magnitude angle of the exodeviation

Baseline, 6-week, 12-week and 24-week
Change of Distance stereoacuity
Tijdsspanne: Baseline, 6-week, 12-week and 24-week

measured by Distance Randot® stereotest, ranged from 400 seconds of arc (the worst measurable stereoacuity) to 60 seconds of arc (the best measurable stereoacuity )

Baseline, 6-week, 12-week and 24-week
Change of Near stereoacuity
Tijdsspanne: Baseline, 6-week, 12-week and 24-week

measured by Preschool Randot® stereoacuity test, ranged from 800 seconds of arc (the worst measurable stereoacuity) to 40 seconds of arc (the best measurable stereoacuity )

Baseline, 6-week, 12-week and 24-week
Change of Quality of Life (QoL) measures - Chinese Intermittent Exotropia Questionnaire (CIXTQ) for children aged 5 to 17 and parents of children aged 2 to 17
Tijdsspanne: Baseline, 12-week and 24-week

Part a: Child CIXTQ - 12 items completed by children, simplified 3-point scale (0, 50 and 100); Part b: Proxy CIXTQ - 12 items completed by parents to evaluate their child's health-related quality-of-life (HRQoL) from a parental perspective, 5-point Likert-type (0, 25, 50, 75, and 100); Part c: Parent CIXTQ - 17 items to measure the parent's own HRQoL, 5-point Likert-type (0, 25, 50, 75 and 100). The higher the score, the better the outcome (QoL).

Baseline, 12-week and 24-week
Change of Quality of Life (QoL) measures - The Chinese Adult Strabismus Quality of Life Questionnaire (CAS-20) for adult participants aged 18 or above
Tijdsspanne: Baseline, 12-week and 24-week

20 items to assess psychosocial impact and visual function, 5-point Likert-type (0, 25, 50, 75 and 100). Higher scores indicating better perceived QoL.

Baseline, 12-week and 24-week

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 juni 2026

Primaire voltooiing (Geschat)

1 juni 2028

Studie voltooiing (Geschat)

1 december 2028

Studieregistratiedata

Eerst ingediend

3 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

10 juni 2026

Eerst geplaatst (Werkelijk)

11 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

23 september 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • HSEARS20251213004

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren